Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 8,269 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Risk Clear all

Conditions: Alzheimer Disease
Interventions: eHealth Platform, Videoconference Telehealth Platform; Other
Lead sponsor: Banner Health; Other
Eligibility: 60 Years to 80 Years
Enrollment: 681 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Mt. Pleasant, South Carolina • Bristol, Tennessee

Conditions: Hyperlipidemia
Interventions: Bococizumab (PF-04950615;RN316), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 58
States / cities: Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 45 more

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Placebo, Standard of Care; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: San Diego, California • Farmington, Connecticut • Miami, Florida + 14 more

Conditions: Colonic Polyps
Interventions: Capsule swallow; Device
Lead sponsor: Capso Vision, Inc.; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 11
States / cities: Chula Vista, California • Lancaster, California • Orange, California + 8 more

Conditions: Mental Health
Interventions: Behavioral Parent Training; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Myelodysplastic Syndromes
Interventions: ASTX727 LD, ASTX727 SD; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 18
States / cities: Birmingham, Alabama • Aurora, Colorado • New Haven, Connecticut + 14 more

Conditions: Preeclampsia, Aspirin, Clinical Decision Support Systems, Economics, Behavioral
Interventions: Electronic health record best practice alert; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: Female only
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: F01.145.802.845, F01.145.802.987
Interventions: Project Prepared, TEEN; Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 12 Years to 14 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Julie E. Bauman, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions: Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation, Docetaxel; Drug · Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Neuroblastoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: fenretinide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 25
States / cities: Duarte, California • Long Beach, California • Los Angeles, California + 19 more

Conditions: Immune System, Stress, Chronic Stress, Cardiovascular Health
Interventions: Peanuts, roasted, salted with skins, Isocaloric food; Other
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Davis, California

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 3,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more

Conditions: Trichomonas Vaginitis, Chlamydia Trachomatis, Neisseria Gonorrhoeae Infection
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 15 Years and older · Female only
Enrollment: 305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Localized Childhood Soft Tissue Sarcoma, Rhabdomyosarcoma, Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
Interventions: Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Vincristine Sulfate; Drug · Biological · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 49 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 196
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 142 more

Conditions: Venous Thromboembolism
Interventions: Not listed
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years and older
Enrollment: 21,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Cardiac Pacemaker, Cardiac Rhythm Disorder, Bradycardia
Interventions: AVEIR remote care system; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Newport Beach, California

Conditions: Studying the Genetic Relationship of Rotator Cuff Tears
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2028
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Breast Cancer
Interventions: Ultrahypofractionated Radiation, Moderately Hypofractionated Radiation; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Loveland, Colorado • Jacksonville, Florida • Voorhees Township, New Jersey + 2 more

Conditions: Penicillin Allergy
Interventions: Amoxicillin; Drug
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Danville, Pennsylvania • Lewiston, Pennsylvania • Scranton, Pennsylvania + 1 more

Conditions: Hypertension, Cardiovascular Disease Risk
Interventions: Complex quality improvement intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Kinston, North Carolina

Conditions: Significant Bleeding Risk
Interventions: Octaplex, Beriplex P/N (Kcentra); Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more

Conditions: Infections, Papillomavirus
Interventions: Data collection; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Pediatric Obesity, Type 2 Diabetes, Metabolic Syndrome
Interventions: Family Focused Lifestyle Intervention; Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 8 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Evaluation of Self-Mediated Alternatives for Risk Testing Education and Return of Results

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

Prospective, Open-label, Non-significant Risk, Multicenter Study Comparing the Polyp Detection of the Study Device to That of the Colonoscopy Reference

Pediatricians Building Resilience Through Early Identification for Toddler Well-Being

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Low Dose Aspirin Alerts in High-Risk Pregnancies

Project Prepared: Risks, Roles and Relationships

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Fenretinide in Treating Children With Solid Tumors

Impact of Peanut Consumption on Stress, Immune Function, Inflammation, and Cardiovascular Health in High-Stress Individuals

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

AVEIR Remote Care System Non-Significant Risk Study

Genetic Factors Affecting Risks for Rotator Cuff Disease

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

Geisinger Antibiotic Allergy Pilot Program: Assess and Address

Improving Care for Patients With High Blood Pressure

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada

A Family Based Intervention to Reduce the Risk of Type 2 Diabetes in Children